Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
oleh: Elisa I. Rivas, Jenniffer Linares, Melissa Zwick, Andrea Gómez-Llonin, Marc Guiu, Anna Labernadie, Jordi Badia-Ramentol, Anna Lladó, Lídia Bardia, Iván Pérez-Núñez, Carolina Martínez-Ciarpaglini, Noelia Tarazona, Anna Sallent-Aragay, Marta Garrido, Toni Celià-Terrassa, Octavio Burgués, Roger R. Gomis, Joan Albanell, Alexandre Calon
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-09-01 |
Deskripsi
A substantial proportion of HER2+ breast cancer patients do not benefit from HER2-targeted therapy. Here, the authors identify a population of cancer-associated fibroblasts involved in the suppression of trastuzumab-induced ADCC that can be pharmacologically targeted to raise treatment effectiveness in unresponsive tumors.